CA3135388A1 - Pyrimidine jak inhibitors for the treatment of skin diseases - Google Patents
Pyrimidine jak inhibitors for the treatment of skin diseases Download PDFInfo
- Publication number
- CA3135388A1 CA3135388A1 CA3135388A CA3135388A CA3135388A1 CA 3135388 A1 CA3135388 A1 CA 3135388A1 CA 3135388 A CA3135388 A CA 3135388A CA 3135388 A CA3135388 A CA 3135388A CA 3135388 A1 CA3135388 A1 CA 3135388A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically
- mmol
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837827P | 2019-04-24 | 2019-04-24 | |
| US62/837,827 | 2019-04-24 | ||
| PCT/US2020/029466 WO2020219640A1 (en) | 2019-04-24 | 2020-04-23 | Pyrimidine jak inhibitors for the treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3135388A1 true CA3135388A1 (en) | 2020-10-29 |
Family
ID=70779856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3135388A Pending CA3135388A1 (en) | 2019-04-24 | 2020-04-23 | Pyrimidine jak inhibitors for the treatment of skin diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11439641B2 (https=) |
| EP (1) | EP3959213B1 (https=) |
| JP (1) | JP7482152B2 (https=) |
| AR (1) | AR118767A1 (https=) |
| CA (1) | CA3135388A1 (https=) |
| ES (1) | ES2994097T3 (https=) |
| HR (1) | HRP20241053T1 (https=) |
| HU (1) | HUE067909T2 (https=) |
| PL (1) | PL3959213T3 (https=) |
| TW (1) | TW202106681A (https=) |
| WO (1) | WO2020219640A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108613A1 (zh) * | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| CN116390922B (zh) * | 2020-10-21 | 2025-07-18 | 珠海联邦制药股份有限公司 | 硒杂环类化合物及其应用 |
| WO2022094174A1 (en) * | 2020-10-30 | 2022-05-05 | Children's Hospital Medical Center | Compositions and methods for the treatment of esophageal conditions |
| JP2024516299A (ja) * | 2021-05-03 | 2024-04-12 | インサイト・コーポレイション | 結節性痒疹の治療のためのルキソリチニブ |
| UA129643C2 (uk) | 2021-05-03 | 2025-06-18 | Інсайт Корпорейшн | Інгібітори шляху jak1 для лікування вузлуватого свербця |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (https=) | 2014-08-21 | 2018-03-31 | ||
| ES2753159T3 (es) | 2015-05-28 | 2020-04-07 | Theravance Biopharma R&D Ip Llc | Compuestos de naftiridina como inhibidores de quinasa JAK |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020108613A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) * | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 TW TW109113573A patent/TW202106681A/zh unknown
- 2020-04-23 WO PCT/US2020/029466 patent/WO2020219640A1/en not_active Ceased
- 2020-04-23 HR HRP20241053TT patent/HRP20241053T1/hr unknown
- 2020-04-23 US US16/856,283 patent/US11439641B2/en active Active
- 2020-04-23 HU HUE20727424A patent/HUE067909T2/hu unknown
- 2020-04-23 ES ES20727424T patent/ES2994097T3/es active Active
- 2020-04-23 EP EP20727424.2A patent/EP3959213B1/en active Active
- 2020-04-23 PL PL20727424.2T patent/PL3959213T3/pl unknown
- 2020-04-23 CA CA3135388A patent/CA3135388A1/en active Pending
- 2020-04-23 AR ARP200101151A patent/AR118767A1/es not_active Application Discontinuation
- 2020-04-23 JP JP2021562812A patent/JP7482152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3959213A1 (en) | 2022-03-02 |
| TW202106681A (zh) | 2021-02-16 |
| ES2994097T3 (en) | 2025-01-17 |
| JP7482152B2 (ja) | 2024-05-13 |
| PL3959213T3 (pl) | 2024-11-04 |
| HUE067909T2 (hu) | 2024-11-28 |
| US20200338073A1 (en) | 2020-10-29 |
| AR118767A1 (es) | 2021-10-27 |
| WO2020219640A1 (en) | 2020-10-29 |
| JP2022529371A (ja) | 2022-06-21 |
| EP3959213C0 (en) | 2024-06-05 |
| EP3959213B1 (en) | 2024-06-05 |
| US11439641B2 (en) | 2022-09-13 |
| HRP20241053T1 (hr) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3959213B1 (en) | Pyrimidine jak inhibitors for the treatment of skin diseases | |
| US11845747B2 (en) | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors | |
| US12172994B2 (en) | Pyrimidine compound as JAK kinase inhibitor | |
| CA3020506A1 (en) | Pyrimidine compounds as jak kinase inhibitors | |
| OA19911A (en) | Pyrimidine compound as JAK kinase inhibitor. | |
| HK40029509A (en) | Pyrimidine compound as jak kinase inhibitor | |
| HK40029509B (en) | Pyrimidine compound as jak kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240423 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250418 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250418 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250530 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251202 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251202 |